Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 67

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 67
---
Supernus Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share data)June 30,December 31,20252024(unaudited)AssetsCurrent assetsCash and cash equivalents$144,711 $69,331 Marketable securities377,885 384,281 Accounts receivable, net140,831 142,077 Inventories, net44,023 54,293 Prepaid expenses and other current assets31,416 36,088 Total current assets738,866 686,070 Property and equipment, net11,069 11,545 Intangible assets, net481,307 521,912 Goodwill117,019 117,019 Deferred income tax assets, net6,181 — Other assets27,963 31,527 Total assets$1,382,405 $1,368,073 Liabilities and stockholders' equityCurrent liabilitiesAccounts payable and accrued liabilities$77,739 $76,352 Accrued product returns and rebates180,916 168,705 Contingent consideration, current portion— 47,340 Other current liabilities27,705 — Total current liabilities286,360 292,397 Operating lease liabilities, long-term24,383 27,382 Deferred income tax liabilities, net— 4,961 Other liabilities7,762 7,600 Total liabilities318,505 332,340 Commitments and contingencies (Note 15)Stockholders' equityCommon stock, $0.001 par value; 130,000,000 shares authorized; 56,119,360 and 55,743,095 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively56 56 Additional paid-in capital496,946 479,440 Accumulated other comprehensive loss, net of tax(200)(189)Retained earnings567,098 556,426 Total stockholders' equity1,063,900 1,035,733 Total liabilities and stockholders' equity$1,382,405 $1,368,073 

See accompanying notes.

3

Table of Contents

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Earnings

(in thousands, except share and per share data)

Three Months EndedJune 30,Six Months EndedJune 30,202